{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-085197","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.109878+00:00","generated_at":"2026-06-08T07:01:36.384235+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bluejay Diagnostics Q3 net loss $2.29M; Toray license cut to 7.5% royalty","bullets":["Net loss $2.29M ($2.08/share) for Q3 2023; nine-month loss $7.65M ($7.30/share).","Cash $5.08M as of Sep 30, 2023, down from $10.1M; expects funding into Q1 2024, needs more capital.","Renegotiated Toray license: royalty reduced from 15% to 7.5% for 10 years; 50% reduction after patent expiry.","Plans to submit FDA 510(k) for Symphony IL-6 in first half 2024 based on August 2023 feedback.","Also renegotiated supply agreement with Toray for cartridge component supply for clinical studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-085197","json":"https://secwatch.observer/filing/0001213900-23-085197.json","markdown":"https://secwatch.observer/filing/0001213900-23-085197.md","text":"https://secwatch.observer/filing/0001213900-23-085197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023085197/0001213900-23-085197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023085197/ea187862-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:01:36.384235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"45a834b7f362cafd715ec2b3eb97374234abe4ce","claim":"Bluejay Diagnostics, Inc. reported the three and nine months ended September 30, 2023 results: net income $2.29 million and $7.65 million, EPS $2.08 and $7.30 per share.","evidence_excerpt":"the net loss for the three and nine months ended September 30, 2023 was $2.29 million and $7.65 million, or $2.08 and $7.30 per share, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023085197/0001213900-23-085197-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Net income","value":"$2.29 million and $7.65 million"},{"label":"EPS","value":"$2.08 and $7.30 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}